Recombinant GH replacement in hypopituitary adults improves endothelial cell function and reduces calculated absolute and relative coronary risk

Clinical Endocrinology

Volumn 61, Issue 3, 2004, Pages 387-393

  Abdu, T A M ^a   Elhadd, T A ^a   Buch, H ^b   Barton, D ^b   Neary, R ^b   Clayton, R N ^a,b,c  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^c UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; LIPID; RECOMBINANT GROWTH FACTOR; SOMATOMEDIN C; THROMBOMODULIN; TRIACYLGLYCEROL;

ANTHROPOMETRIC PARAMETERS; ARTERY DILATATION; ARTERY INTIMA; ARTICLE; BIOPHYSICS; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CAROTID ARTERY; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY RISK; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; INFLAMMATION; LIPID BLOOD LEVEL; MALE; OPEN STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; THICKNESS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

ADULT; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CAROTID ARTERIES; CHOLESTEROL, HDL; CORONARY DISEASE; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FEMALE; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REGIONAL BLOOD FLOW; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TUNICA INTIMA; VASODILATION;

EID: 4644354406     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2004.02109.x     Document Type: Article

References (46)

1. Abdu, T.A., Neary, R., Elhadd, T.A., Akber, M. & Clayton, R.N. (2001) Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clinical Endocrinology (Oxford), 55, 209-216.
2. Ahmad, A.M., Hopkins, M.T., Weston, P.J., Fraser, W.D. & Vora, J.P. (2002) Effects of GH replacement on 24-h ambulatory blood pressure and its circadian rhythm in adult GH deficiency. Clinical Endocrinology (Oxford), 56, 431-437.
3. Anderson, K.M., Odell, P.M., Wilson, P.W.F. & Kannel, W.B. (1991) Cardiovascular disease risk profiles. American Heart Journal, 121, 293-298.
4. Asayama, K., Amemiya, S., Kusano, S. & Kato, K. (1984) Growth hormone induces changes in postheparin plasma lipoprotein lipase and hepatic triglyceridase activities. Metabolism, 33, 129-131.
5. Beshyah, S.A., Henderson, A., Niththyananthan, R., Skinner, E., Anyaoku, V., Richmond, W., Sharp, P. & Johnson, D.G. (1995) The effect of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. Journal of Clinical Endocrinology and Metabolism, 80, 356-363.
6. Beshyah, S.A. & Johnston, D. (1999) Cardiovascular disease and risk factors in adults with hypopituitarism. Clinical Endocrinology (Oxford), 50, 1-15.
7. Binnerts, A., Stewart, G., Wilson, J.H.P., Hoogerbrugge, N., Pols, H.A.P., Birkenhager, J.C. & Lambert, S.W.J. (1992) The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clinical Endocrinology (Oxford), 37, 97-87.
8. Blackett, P.R., Weech, P.K., McConathy, W.J. & Fesmire, J.D. (1982) Growth hormone in the regulation of hyperlipidaemia. Metabolism, 31, 117-120.
9. Boger, R.H., Skamira, C., Bode-Boger, S.M., Brabant, G., von zur Muhlen, A. & Frolich, J.C. (1996) Nitric oxide may mediate the haemodynamics effects of recombinant growth hormone in patients with acquired growth hormone deficiency. Journal of Clinical Investigation, 98, 2706-2713.
10. Bulow, B., Hagmar, L., Mikoczy, Z., Nordstroem, C.H. & Erfurth, E.M. (1997) Increased cerebrovascular mortality in patients with hypopituitarism. Clinical Endocrinology (Oxford), 46, 75-81.
11. Capaldo, B., Patti, L., Oliviero, U., Longobardi, S., Pardo, F., Vitale, F., Fazio, S., Di Rella, F., Biondi, B., Lombardi, G. & Sacca, L. (1997) Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism, 82, 1378-1381.
12. Celemajer, D., Sorensen, K., Spiegelhalter, D. & Deanfield, J. (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 340, 1111-1115.
13. Christ, E.R., Chowienczyk, P.J., Sonksen, P.H. & Russel-Jones, D.L. (1999) Growth hormone replacement therapy in adults with growth hormone deficiency improves vascular reactivity. Clinical Endocrinology (Oxford), 51, 21-25.
14. Cuneo, R.C., Salmon, F., Watts, G.F., Hesp, R. & Sonsken, P.H. (1993) Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism, 42, 1519-1523.
15. Eden, S., Wiklund, O., Oscarsson, J., Rosen, T. & Bengtsson, B.A. (1996) Growth hormone treatment of growth hormone deficient adults results in marked increase in Lp (a) and HDL-cholesterol concentrations. Arteriosclerosis and Thrombosis, 13, 296-301.
16. Elhadd, T.A., Abdu, T.A., Oxtoby, J., Kennedy, G., McLaren, M., Neary, R., Belch, J.J. & Clayton, R.N. (2001) Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. Journal of Clinical Endocrinology and Metabolism, 86, 4223-4232.
17. Evans, L.M., Davies, J.S., Goodfellow, J., Rees, J.A.E. & Scanlon, M.F. (1999) Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clinical Endocrinology (Oxford), 50, 457-464.
18. Evans, L.M., Davies, J.S., Anderson, R.A., Ellis, G.R., Jackson, S.K., Lewis, M.J., Frenneaux, M.P., Rees, A. & Scanlon, M.F. (2000) The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. European Journal of Endocrinology, 142, 254-262.
19. Johannsson, G., Marin, P., Lonn, L., Ottosson, M., Stenlof, K., Bjorntorp, P., Sjostrom, L. & Bengtsson, B.A. (1997) Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. Journal of Clinical Endocrinology and Metabolism, 82, 725-726.
20. Johansson, J.-O., Landin, K., Tengborn, L., Rosen, T. & Bengtsson, A.-B. (1994) High fibrinogen and plasminogen activator inhibitor activity in growth hormone deficient adults. Arteriosclerosis and Thrombosis, 14, 434-437.
21. Johansson, J.-O., Landin, K., Tengborn, L., Johansson, G., Tengborn, L. & Bengtsson, A.-B. (1996) Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone deficient adults. Thrombosis and Haemostasis, 76, 422-428.
22. Kvaniscka, J., Marek, J., Kvaniscka, T., Weiss, V., Markova, M., Stepan, P. & Umlaufova, A. (2000) Increase of adhesion molecules, fibrinogen, plasminogen activator inhibitor and orosomucoid in growth hormone deficient adults and its modulation by recombinant human GH replacement. Clinical Endocrinology (Oxford), 52, 543-548.
23. Leese, G.P., Wallymahmed, M., Vanheyningen, C., Tames, F., Wieringa, G. & MacFarlane, I.A. (1998) HDL-cholesterol reduction associated with adult growth hormone replacement. Clinical Endocrinology, 49, 673-677.
24. Markussis, V., Beshyah, S.A., Fisher, C., Sharp, P., Nicholaides, A.N. & Johnston, D. (1992) Detection of premature atherosclerosis by high resolution ultrasonography in symptom free hypopituitary adults. Lancet, 340, 1188-1192.
25. Matthews, J.N., Altman, D.G., Campbell, M.J. & Royston, P. (1990) Analysis of serial measurements in medical research. British Medical Journal, 300, 230-235.
26. Murray, R.D., Wieringa, G.E., Lissett, C.A., Darzy, K.H., Smethurst, L.E. & Shalet, S.M. (2002) Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome. Clinical Endocrinology (Oxford), 56, 525-532.
27. Nilsson, B., Gustavsson-Kadaka, E., Bengtsson, B. & Jonsson, B. (2000) Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival and mortality. Journal of Clinical Endocrinology and Metabolism, 85, 1420-1425.
28. O'Leary, D.H., Polak, J.F., Wolfson, S.K., Bond, M.G., Bommer, W., Sheth, S., Psaty, B.M., Sharrett, A.R. & Manolio, T.A. (1991) Use of ultrasonography to evaluate carotid atherosclerosis in the elderly: the Cardiovascular Health Study. Stroke, 22, 1155-1163.
29. O'Neal, D.N., Hew, F.L., Best, J.D. & Alford, F. (1999) The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo (a) in hypopituitary adults previously treated with conventional replacement therapy. Growth Hormone and IGF Research, 9, 165-173.
30. Pfeifer, M., Verhovec, R., Zizek, B., Prezelj, J., Poredos, P. & Clayton, R.N. (1999) Growth hormone treatment (GH) reverses early atherosclerotic changes in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 84, 453-457.
31. Pinkney, J.H., Stehouwer, C.D., Coppack, S.W. & Yudkin, J.S. (1997) Endothelial dysfunction: cause of insulin resistance syndrome. Diabetes, 46, S9-S13.
32. Ridker, P.M., Hennekens, C.H., Buring, J.E. & Rifai, N. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine, 342, 836-843.
33. Rosen, T. & Bengtsson, B.-A. (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet, 336, 285-288.
34. Russell-Jones, D.L., Watts, G.F., Weisberger, A., Naoumova, R., Myers, J., Thompson, G.R. & Sonksen, P.H. (1994) The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clinical Endocrinology (Oxford), 41, 345-350.
35. Salomon, F., Cuneo, R.C, Hesp, R., Sonksen, P.H. (1989) The effect of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. New England Journal of Medicine, 321, 1797-1803.
36. Salonen, J.T. & Salonen, R. (1993) Ultrasound B-mode imaging in observational studies of atherosis progression. Circulation (Supplement II), 87, 56-65.
37. Sesmilo, G., Biller, B.M., Llevadot, J., Hayden, D., Hanson, D., Rifai, N. & Klibanski, A. (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Annals of Internal Medicine, 133, 111-122.
38. Sesmilo, G., Miller, K., Hayden, D. & Klibanski, A. (2001) Inflammatory cardiovascular risk markers in women with hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 86, 5774-5781.
39. Sitzer, M., Markus, H.S., Mendall, M.A., Liehr, R., Knorr, U. & Steinmetz, H. (2002) C-reactive protein and carotid intimal medial thickness in a community population. Journal of Cardiovascular Risk, 9, 97-103.
40. Smith, J.C., Evans, L.M., Wilkinson, I., Goodfellow, J., Cockcroft, J.R., Scanlon, M.F. & Davies, J.S. (2002) Effects of GH replacement on endothelial function and large artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clinical Endocrinology (Oxford), 56, 493-501.
41. Tomlinson, J.W., Holden, N., Hills, R., Wheatley, K., Clayton, R.N., Bates, A.S., Sheppard, M.C. & Stewart, P.M. (2001) Premature mortality in 1014 patients with hypopituitarism. Lancet, 357, 425-431.
42. Vahl, N., Jorgensen, J.O., Hansen, T.B., Klausen, I.B. & Christiansen, J.S. (1998) The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12 month placebo-controlled study. International Journal of Obesity and Related Metabolic Disorders, 22, 529-536.
43. Vane, J.R., Angaard, E.E. & Botting, R.M. (1990) Regulatory functions of vascular endothelium. New England Journal of Medicine, 323, 27-36.
44. Weaver, J.U., Monson, J.P., Noonan, K., John, W.G., Edwards, A., Evans, K.A. & Cunningham, J. (1995) The effect of low dose recombinant growth hormone replacement on regional fat distribution, insulin sensitivity and cardiovascular risk factors in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism, 80, 153-159.
45. Webster, J.M., Stewart, M., al-Maskari, M., Osman, I., Kendall-Taylor, P., Mitcheson, J. & Laker, M.F. (1997) The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein (a) in growth hormone-deficient adults. Atherosclerosis, 133, 115-121.
46. Yudkin, J.S., Stehouwer, C.D., Emies, J.J. & Coppack, S.W. (1999) Creactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arteriosclerosis, Thrombosis and Vascular Biology, 19, 972-978.